Helping to transform lives with innovative antibody-drug conjugate therapies
Our Science
We are driven to boldly develop and deliver breakthrough therapies for cancer.
Learn MoreTechnologies and Platforms
A game-changing antibody-drug conjugate (ADC) platform that directs potent toxins to the tumor and tumor micro-environment to improve effectiveness and tolerability
Learn MoreCareers
Join a team committed to excellence and innovation — dedicated to developing the next generation of cancer therapies
Learn MorePatients
“Every day is precious. I treasure every opportunity to choose life, and have more time in the world with the people I love.”
Learn MoreOur Company
We take on some of the toughest challenges facing medical science today. We are a leader in next-generation antibody-drug conjugate technology, committed to help transform the lives of people with cancer.
Learn More
Latest
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer
Learn More
Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
Learn More
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
Learn More
“The FDA approval of our first ADC therapy is our most prominent example of how we are delivering on our mission for all stakeholders: the triple-negative breast cancer (TNBC) community, our employees at Immunomedics, our stockholders, and our business partners and stakeholders.”